|
|
|
|
Protein Therapeutics Markets (Antithrobins, Cytokines, Growth Hormones, Hematopoietics, Insulin, Monoclonal An
Published By: Kalorama Information Page Count: 250 Order Code: R566-465 Description The substances utilized for what is commonly referred to as 'protein therapeutics' have one thing in common --- they are all composed primarily of -amino...
|
|
|
Bradmer Issued Patent in Europe for Use of Neuradiab to Treat Lymphoma
/PRNewswire-FirstCall/ - Bradmer Pharmaceuticals Inc., a biopharmaceutical company dedicated to the development and commercialization of cancer therapies, announced today that it has been granted European Patent, # 1351713, entitled 'Anti...
|
|
|
Japan drug giant Takeda bets big on Bay Area facility
San Francisco Business Times - by Leena Rao Paolo Vescia Takeda put its antibody research center in the Bay Area due to the regions prominence in the field, says Haak-Frendscho.Related News Japanese drug giant Takeda Pharmaceutical Co.
|
|
|
Oxoid Offers Range Of Tests For Influenza Virus Types A And B
Oxoid, a world leading microbiology brand, offers a range of valuable diagnostic tools for the detection of respiratory disease caused by influenza virus Types A and B.Rapid diagnosis of Influenza A or B virus infections plays an...
|
|
|
RoACTEMRA, a Humanized Anti-Human IL-6 Receptor Monoclonal Antibody, Receives Positive Opinion in Europe for t
(Tokyo) - Chugai Pharmaceutical Co., Ltd.[Head Office: Chuo-ku, Tokyo; President Osamu Nagayama (hereafter, 'Chugai')] and F. Hoffmann-La Roche Ltd. [Head Office: Basel, Switzerland. CEO: Severin Schwan (hereafter, 'Roche')]...
|
|
|
::: RoACTEMRA, a Humanized Anti-Human IL-6 Receptor Monoclonal Antibody, Receives Positive Opinion in Europe
(Tokyo) - Chugai Pharmaceutical Co., Ltd.[Head Office: Chuo-ku, Tokyo; President Osamu Nagayama (hereafter, 'Chugai')] and F. Hoffmann-La Roche Ltd. [Head Office: Basel, Switzerland. CEO: Severin Schwan (hereafter, 'Roche')]...
|
|
|
Clinical Data Participates in MAb IMPACT Meeting to Improve Clinical Efficacy of Monoclonal Antibodies for Can
NEWTON, Mass.-- (BUSINESS WIRE) -- PGxHealth, a division of (NASDAQ: CLDA), today announced its participation in the international mAb IMPACT meeting which is focused on IMProving ACTivation of the FCGR3A pathway for optimizing the treatment...
|
|
|
Health Robotics Announces $60M Investment by Devon International Group and ITOCHU Inc. in the CytoCare(TM) and
BOZEN, Italy, November 21 /PRNewswire/ -- Health Robotics today announced that it has signed a definitive agreement with Devon International Group (DIG) and its strategic partner ITOCHU International, Inc., whereby DIG and ITOCHU have...
|
|
|
Health Robotics Announces $60M Investment by Devon International Group and ITOCHU Inc. in the CytoCare(TM) and
BOZEN, Italy, November 21 /PRNewswire/ -- Health Robotics today announced that it has signed a definitive agreement with Devon International Group (DIG) and its strategic partner ITOCHU International, Inc., whereby DIG and ITOCHU have...
|
|
|
Health Robotics Announces $60M Investment by Devon International Group and ITOCHU Inc. in the CytoCare(TM) and
KSLA Health Connections Health BOZEN, Italy, November 21 /PRNewswire/ -- Health Robotics today announced that it has signed a definitive agreement with Devon International Group (DIG) and its strategic partner ITOCHU International, Inc.,...
|
|
|
Health Robotics Announces $60M Investment by Devon International Group and ITOCHU Inc. in the CytoCare(TM) and
Latest Health News BOZEN, Italy, November 21 /PRNewswire/ -- Health Robotics today announced that it has signed a definitive agreement with Devon International Group (DIG) and its strategic partner ITOCHU International, Inc., whereby DIG and...
|
|
|
Health Robotics Announces $60M Investment by Devon International Group and ITOCHU Inc. in the CytoCare(TM) and
Latest Health News BOZEN, Italy, November 21 /PRNewswire/ -- Health Robotics today announced that it has signed a definitive agreement with Devon International Group (DIG) and its strategic partner ITOCHU International, Inc., whereby DIG and...
|
|
|
Health Robotics Announces $60M Investment by Devon International Group and ITOCHU Inc. in the CytoCare(TM) and
Latest Health News BOZEN, Italy, November 21 /PRNewswire/ -- Health Robotics today announced that it has signed a definitive agreement with Devon International Group (DIG) and its strategic partner ITOCHU International, Inc., whereby DIG and...
|
|
|
Monoclonal Antibodies - New monoclonal antibodies research from Yonsei University, Medical Department outlined
In this recently published study, investigators in Seoul, South Korea conducted a study 'To report on the clinical characteristics and treatment outcomes of (CMV) retinitis cases that occurred after hematopoietic (HSCT) using an alemtuzumab...
|
|
|
Monoclonal Antibodies - University of Lubeck details research in monoclonal antibodies
In this recent report, researchers in Lubeck, Germany conducted a study 'To investigate the vitreous levels of and vascular growth factor-A (VEGF-A) after intravitreal injection of the drug in patients with choroidal neovascularization (CNV)...
|
|
|
Clinical Data Participates in MAb IMPACT Meeting to Improve Clinical Efficacy of Monoclonal Antibodies for Can
- PGxHealth, a division of Clinical Data, Inc.(NASDAQ: CLDA), today announced its participation in the international mAb IMPACT meeting which is focused on IMProving ACTivation of the FCGR3A pathway for optimizing the treatment of cancer....
|
|
|
Clinical Data Participates in MAb IMPACT Meeting to Improve Clinical Efficacy of Monoclonal Antibodies for Can
- PGxHealth The approach of applying pharmacogenetics to develop drugs and predictive tests based on a critical pathway, such as FCGR3A, offers greater opportunity for us to understand the mechanisms of action of monoclonal antibodies and to...
|
|
|
Anti-CCR5 Monoclonal Antibody Has Strong Anti-HIV Activity
_ Anti-CCR5 Monoclonal Antibody Has Strong Anti-HIV Activity.
|
|
|
Life Science Pharmaceuticals, Inc
Enters Into Agreement with Abbott Laboratories (ABT) to Develop Antibody 806 11/17/2008 6:29:23 AM More...Ludwig Institute For Cancer Research (LICR)Release: Clinical Trial Confirms Novel EGFR Antibody Targets Tumors But Not Normal...
|
|
|
Learn about the Forensic Technologies: New and Growing Markets
Technology advancements in forensics have been of considerable import in recent years.Recent examples include improved fingerprint recovery from metals, such as gun cartridges and bomb fragments, use of the chemistry of color to identify...
|
|
|
Medarex and Massachusetts Biologic Laboratories Announce Primary Objective Achieved in Phase 2 Trial of Monocl
Medarex and Massachusetts Biologic Laboratories Announce Primary Objective Achieved in Phase 2 Trial of Monoclonal Antibody Combination for the Treatment of Clostridium difficile Associated Diarrhea (CDAD) 2008 NOV 19 - (NewsRx.com) --...
|
|
|
Monoclonal Antibodies: Recent findings in monoclonal antibodies described by investigators from Chugai Pharmac
Recent findings in monoclonal antibodies described by investigators from Chugai Pharmaceutical Co., Ltd., Research Department (NewsRx.com) -- New investigation results, 'Anti-IL-6 receptor antibody increases blood IL-6 level via the blockade...
|
|
|
Intellect Neurosciences, Inc
Validates Pivotal European Patent for Alzheimer's Monoclonal Antibody Platform 11/11/2008 9:45:57 AM More...Intellect Neurosciences, Inc.Grants to Top Tier Global Pharmaceutical Company an Option to License Certain Alzheimer's...
|
|
|
Intellect Neurosciences, Inc. Validates Pivotal European Patent for Alzheimer's Monoclonal Antibody Platform
/PRNewswire-FirstCall/ -- a biopharmaceutical company focused on development of disease-modifying therapeutic agents for the treatment and prevention of Alzheimer's disease (AD), announced today that it has completed validation of its...
|
|
|
FibroGen Announces New Research on HIF-PHI and Anti-CTGF Development Programs in Chronic Kidney Disease
- FibroGen, Inc.today announced data from research on its therapeutic programs related to hypoxia-inducible factor (HIF) prolyl hydroxylase inhibitors (PHI) and anti-connective tissue growth factor (anti-CTGF) were reported at the 41st...
|
